Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.33 |
| ▸ | CTSS | P25774 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19334263 | 0.91 | CTSK (0.35) | CTSKCTSS | |
| SCHEMBL19578425 | 0.88 | CTSK (0.36) | CTSKCTSSTSHRLMNACYP3A4 | |
| SCHEMBL19578133 | 0.84 | CTSK (0.35) | CTSKCTSSTSHRLMNACYP3A4 | |
| SCHEMBL19334205 | 0.81 | CTSK (0.35) | CTSKCTSS | |
| SCHEMBL19578342 | 0.80 | TSHR (0.37) | CTSKTSHRLMNACYP3A4NFKB1 | |
| SCHEMBL19318525 | 0.79 | CTSS (0.34) | CTSKCTSS | |
| SCHEMBL8906249 | 0.79 | CTSS (0.34) | CTSKCTSS | |
| SCHEMBL19578131 | 0.77 | CTSK (0.40) | CTSKCTSS | |
| SCHEMBL22361396 | 0.77 | EPHX1 (0.39) | CTSKCTSSTSHRCYP3A4 | |
| SCHEMBL22361402 | 0.77 | EPHX1 (0.39) | CTSKCTSSTSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | CTSK 789/4885CTSS 864/4885TSHR 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.